Candesartan cilexetil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319525

CAS#: 145040-37-5

Description: Candesartan cilexetil is a prodrug of the potent, long-acting, and selective angiotensin II type 1 receptor (AT1) antagonist, candesartan. It is rapidly hydrolyzed to candesartan during gastrointestinal absorptio. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathways for angiotensin II synthesis. Candesartan has much greater affinity ( > 10,000-fold) for the AT1 receptor than for the AT2 receptor.

Price and Availability


USD 60
USD 150
USD 550
USD 2450

USD 70
USD 250
USD 950
USD 3950

USD 90
USD 350
USD 1450
Ask price

Candesartan cilexetil purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319525
Name: Candesartan cilexetil
CAS#: 145040-37-5
Chemical Formula: C33H34N6O6
Exact Mass: 610.25398
Molecular Weight: 610.671
Elemental Analysis: C, 64.91; H, 5.61; N, 13.76; O, 15.72

Synonym: TCV-116; TCV 116; TCV116; Candesartan cilexetil

IUPAC/Chemical Name: 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate


InChi Code: InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Yasuno S, Fujimoto A, Nakagawa Y, Kuwahara K, Ueshima K. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther. 2012 May;10(5):577-83. doi: 10.1586/erc.12.34. Review. PubMed PMID: 22651833.

2: Ardiana F, Lestari ML, Indrayanto G. Candesartan cilexetil. Profiles Drug Subst Excip Relat Methodol. 2012;37:79-112. doi: 10.1016/B978-0-12-397220-0.00003-9. Epub 2012 Mar 19. Review. PubMed PMID: 22469317.

3: Joost A, Schunkert H, Radke PW. Candesartan cilexetil: an update. Expert Opin Pharmacother. 2011 Aug;12(11):1769-80. doi: 10.1517/14656566.2011.587000. Epub 2011 Jun 9. Review. PubMed PMID: 21651457.

4: Hoy SM, Keating GM. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension. Am J Cardiovasc Drugs. 2010;10(5):335-42. doi: 10.2165/11206300-000000000-00000. Review. PubMed PMID: 20860416.

5: Mengden T, Uen S, Bramlage P. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. Vasc Health Risk Manag. 2009;5:1043-58. Epub 2009 Dec 29. Review. PubMed PMID: 20057897; PubMed Central PMCID: PMC2801628.

6: Kusumoto K, Mori M, Tanokashira J, Totsuka N. [Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide]. Nihon Yakurigaku Zasshi. 2009 Oct;134(4):217-24. Review. Japanese. PubMed PMID: 19828927.

7: Baguet JP, Barone-Rochette G, Neuder Y. Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. Review. PubMed PMID: 19436650; PubMed Central PMCID: PMC2672439.

8: Meredith PA. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007 Jul;23(7):1693-705. Review. PubMed PMID: 17588300.

9: Féghali RE, Nisse-Durgeat S, Asmar R. Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. Vasc Health Risk Manag. 2007;3(1):165-71. Review. PubMed PMID: 17583187; PubMed Central PMCID: PMC1994048.

10: Plosker GL, Keam SJ. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. Pharmacoeconomics. 2006;24(12):1249-72. Review. PubMed PMID: 17129078.

11: Bönner G, Fuchs W. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. Curr Med Res Opin. 2005 Jun;21(6):935-40. Review. PubMed PMID: 15969893.

12: Fenton C, Scott LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs. 2005;65(4):537-58. Review. PubMed PMID: 15733014.

13: Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Expert Rev Cardiovasc Ther. 2004 Nov;2(6):829-35. Review. Erratum in: Expert Rev Cardiovasc Ther. 2005 May;3(3):543-4. PubMed PMID: 15500428.

14: Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, Hansen KW, Bek T, Mogensen CE. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):96-9. Review. PubMed PMID: 12806591.

15: Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs. 2002;62(8):1253-87. Review. PubMed PMID: 12010090.

16: Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs. 2002;62(5):787-816. Review. PubMed PMID: 11929332.

17: Naka T, Kubo K, Nishikawa K, Inada Y, Furukawa Y. [Angiotensin II receptor antagonists: candesartan cilexetil]. Yakugaku Zasshi. 2000 Dec;120(12):1261-75. Review. Japanese. PubMed PMID: 11193378.

18: Mallion JM, Badguet JP. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data. J Hum Hypertens. 2000 Oct;14 Suppl 2:S33-41. Review. PubMed PMID: 11086634.

19: Mancia G, Grassi G. The role of angiotensin II receptor antagonists in hypertension management: focus on candesartan cilexetil. J Hum Hypertens. 2000 Oct;14 Suppl 2:S3-10. Review. PubMed PMID: 11086630.

20: Zannad F. Preserving target-organ function with candesartan cilexetil in patients with hypertension. Blood Press Suppl. 2000;1:36-9. Review. PubMed PMID: 11059635.